Barclays raised the firm’s price target on Phibro Animal Health (PAHC) to $20 from $13 and keeps an Underweight rating on the shares. The company’s fiscal Q1 “beat and raise” indicates progress, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC: